Safety Profile Overview
Anti-VEGF antibody fragment for wet AMD and DME. Pioneered the anti-VEGF approach to retinal disease treatment.
Generic Name
ranibizumab
Brand Names
Lucentis
Therapeutic Class
Anti-VEGF Monoclonal Antibody
Manufacturer
Roche/Genentech
What Pharma Signal Tracks for Lucentis
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Lucentis, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Lucentis products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Lucentis Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Lucentis.
curl "https://api.pharma-signal.com/drug/safety/lucentis" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Lucentis against other Anti-VEGF Monoclonal Antibody drugs, or explore the full manufacturer portfolio for Roche/Genentech.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Lucentis ranks within Anti-VEGF Monoclonal Antibody on serious event rates.
- Company portfolio risk — View all drugs from Roche/Genentech with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.